Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The porphyrias are a group of uncommon metabolic diseases caused by enzyme deficiencies within heme biosynthesis that lead to neurotoxic or phototoxic heme precursor accumulation. There are four acute porphyrias characterized by neuropsy-chiatric symptoms: acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolevulinic acid dehydratase deficiency porphyria. Treatment includes elimination of any porphyrogenic factor and symptomatic treatment. Carbohydrate and intravenous heme administration constitute specific therapies in the disorders’ acute phase. The mainstay treatment in the cutaneous porphyrias is avoidance of sunlight exposure. In porphyria cutanea tarda and the two acute porphyrias with skin manifestations, variegate porphyria and hereditary coproporphyria, care of the vulnerable skin is important. In porphyria cutanea tarda, specific treatment is accomplished by a series of phlebotomies and/or by low-dose chloroquine administration. In erythropoietic protoporphyria, light-protective beta-carotene is prescribed.
- Anderson KE, Sassa S, Bishop DF, Desnick RJ: Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In The Metabolic and Molecular Bases of Inherited Disease, edn 8. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 2001:2991–3062.
- Badminton MN, Elder GH: Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005, 28:277–286. CrossRef
- Soonawalla ZF, Orug T, Badminton MN, et al.: Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004, 363:705–706. CrossRef
- Stojeba N, Meyer C, Jeanpierre C, et al.: Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 2004, 10:935–938. CrossRef
- McGuire BM, Bonkovsky HL, Carithers RL, Jr, et al.: Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005, 11:1590–1596. CrossRef
- Rand EB, Bunin N, Cochran W, et al.: Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006, 118:e1896–e1899. CrossRef
- Wahlin S, Aschan J, Bjornstedt M, et al.: Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007, 46:174–179. CrossRef
- Deacon AC, Elder GH: ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001, 54:500–507. CrossRef
- Andersson C, Innala E, Bäkström T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med 2003, 254:176–183. CrossRef
- Hift RJ, Meissner PN: An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine 2005, 84:48–60. CrossRef
- Thunell S: (Far) outside the box: genomic approach to acute porphyria. Physiol Res 2006, 55(Suppl 2):S43–S66.
- Anderson KE, Bloomer JR, Bonkovsky HL, et al.: Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005, 142:439–450.
- Kauppinen R: Porphyrias. Lancet 2005, 365:241–252.
- Bonkovsky HL: Neurovisceral porphyrias: what a hematologist needs to know. Hematology Am Soc Hematol Educ Program 2005:24–30.
- Sassa S: Modern diagnosis and management of the porphyrias. Br J Haematol 2006, 135:281–292. CrossRef
- Schreiber A, Elitok S, Kettritz R: Solving electrolyte disturbances with the Ehrlich reagent. Nephrol Dial Transplant 2003, 18:1217–1219. CrossRef
- The European Porphyria Initiative website. http://www.porphyria-europe.org. Accessed July 10, 2007.
- Thunell S, Bjernevik K, Thunell G, Harper P: Patient’s and Doctor’s Guide to Medication in Acute Porphyria 2005. Stockholm: Swedish Porphyria Association; 2005.
- Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI: Reconstitution of hematin for intravenous infusion. Ann Intern Med 2006, 144:537–538.
- Castelo-Branco C, Vicente JJ, Vanrell JA: Use of gonado-tropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria. Metabolism 2001, 50:995–996. CrossRef
- Floderus Y, Sardh E, Moller C, et al.: Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem 2006, 52:701–707. CrossRef
- Badminton MN, Deybach JC: Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 2006, 13:668–669. CrossRef
- Seiden WB, Kelly LP, Ali R: Acute intermittent porphyria associated with ovarian stimulation. A case report. J Reprod Med 2003, 48:201–203.
- Wang JG, Guarnaccia M, Weiss SF, et al.: Initial presentation of undiagnosed acute intermittent porphyria as a rare complication of ovulation induction. Fertil Steril 2006, 86:462.e1–462.e3. CrossRef
- The Drug Database for Acute Porphyria website. http://www.drugs-porphyria.org. Accessed July 10, 2007.
- Thunell S, Pomp E, Brun A: Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 2007 [Epub ahead of print].
- Porphyria South Africa website. http://www.uct.ac.za/depts/porphyria. Accessed July 10, 2007.
- The American Porphyria Foundation website. http://www.porphyriafoundation.com. Accessed July 10, 2007.
- The Canadian Porphyria Foundation. http://www.cpf-inc.ca. Accessed July 10, 2007.
- Deybach JC, Badminton M, Puy H, et al.: European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 2006, 55(Suppl 2):S67–S73.
- Andant C, Puy H, Bogard C, et al.: Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000, 32:933–939. CrossRef
- Harper P, Sardh E, Henrichson A, et al.: Plasma porphyrin precursors and porphyrins in AIP-patients with chronic renal failure [abstract S06-3]. Paper presented at the Porphyrins and Porphyrias International Meeting. Rotterdam, The Netherlands; April 29–May 3, 2007. http://www2.eur.nl/fgg/emco/porphyrias2007/downloads/abstractbook.pdf. Accessed September 26, 2007.
- Sardh E, Rejkjaer L, Andersson DE, Harper P: Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet 2007, 46:335–349. CrossRef
- Andersson C, Peterson J, Anderson K, et al.: Randomized clinical trial of recombinant human porphobilinogen deaminase (rhPBGD) in acute attacks of porphyria [abstract S06-5]. Paper presented at the Porphyrins and Porphyrias International Meeting. Rotterdam, The Netherlands; April 29–May 3, 2007. http://www2.eur.nl/fgg/emco/porphyrias2007/downloads/abstractbook.pdf. Accessed September 26, 2007.
- Nowak G, Yin Z, Ellis EC, et al.: Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Transplantation 2006, 82(Suppl 2):216–217.
- Johansson A, Nowak G, Möller C, et al.: Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther 2004, 10:337–343. CrossRef
- González-Aseguinolaza G, Prieto J, Rodríguez-Pena M, et al.: AAV-mediated liver-specific expression of porphobilinogen deaminase protects against acute attack induced by Phenobarbital injection in a mouse model of acute intermittent porphyria [abstract S05-5]. Paper presented at the Porphyrins and Porphyrias International Meeting. Rotterdam, The Netherlands; April 29–May 3, 2007. http://www2.eur.nl/fgg/emco/porphyrias2007/downloads/abstractbook.pdf. Accessed September 26, 2007.
- Badminton MN, Elder GH: Management of acute and cutaneous porphyrias. Int J Clin Pract 2002, 56:272–278.
- Kostler E, Wollina U: Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005, 6:377–383. CrossRef
- Thunell S, Harper P: Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda—suggestions for a handling programme. Scand J Clin Lab Invest 2000, 60:561–579. CrossRef
- Wiman A, Floderus Y, Harper P: Novel mutations and phenotypic effect of the splice site modulator IVS3-48C in nine Swedish families with erythropoietic protoporphyria. J Hum Genet 2003, 48:70–76. CrossRef
- Thunell S, Harper P, Brun A: Porphyrins, porphyrin metabolism and porphyrias. IV. Pathophysiology of erythyropoietic protoporphyria—diagnosis, care and monitoring of the patient. Scand J Clin Lab Invest 2000, 60:581–604. CrossRef
- Holme SA, Anstey AV, Finlay AY, et al.: Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006, 155:574–581. CrossRef
- Wahlin S, Harper P, Brun A: Protection from phototoxic injury in erythropoietic protoporphyria [abstract S07-3]. Paper presented at the Porphyrins and Porphyrias International Meeting. Rotterdam, The Netherlands; April 29–May 3, 2007. http://www2.eur.nl/fgg/emco/porphyrias2007/downloads/abstractbook.pdf. Accessed September 26, 2007.
- Anstey AV, Hift RJ: Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut 2007, 56:1009–1018.
- Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria
Current Treatment Options in Gastroenterology
Volume 10, Issue 6 , pp 444-455
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links